Reven Pharmaceuticals Stock
Pharmaceuticals
About Reven Pharmaceuticals Stock
Reven Pharmaceuticals, Inc. is a development-stage bio-pharmaceutical company that develops and markets propriety solutions for the treatment of cardiovascular and circulatory related conditions. These non-surgical, minimally invasive treatments have shown to improve vascular function and circulation without invasive medical procedures, such as atherectomy or balloon angioplasty and stents.
Funding History
| January 2014 | $1.8M |
|---|---|
| February 2015 | $4.4M |
| January 2016 | $10.0M |
| January 2017 | $23.0M |
| January 2019 | $23.0M |
Management
Co-Founder & Chief Executive Officer
Peter Lange
Chief Financial Officer
Michael Volk
Chief Operating Officer
Brian Denomme
Chief Technology Officer
James Ervin
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Reven Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
